| Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals PJ Brennan, RVV Tatituri, M Brigl, EY Kim, A Tuli, JP Sanderson, ... Nature immunology 12 (12), 1202-1211, 2011 | 378 | 2011 |
| Activation of T cells by carbamazepine and carbamazepine metabolites Y Wu, JP Sanderson, J Farrell, NS Drummond, A Hanson, E Bowkett, ... Journal of allergy and clinical immunology 118 (1), 233-241, 2006 | 173 | 2006 |
| Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling JP Sanderson, DJ Naisbitt, J Farrell, CA Ashby, MJ Tucker, MJ Rieder, ... The Journal of Immunology 178 (9), 5533-5542, 2007 | 156 | 2007 |
| Role of bioactivation in drug-induced hypersensitivity reactions JP Sanderson, DJ Naisbitt, BK Park The AAPS journal 8 (1), 55-64, 2006 | 83 | 2006 |
| Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3β loop G Matulis, JP Sanderson, NM Lissin, MB Asparuhova, GR Bommineni, ... PLoS biology 8 (6), e1000402, 2010 | 82 | 2010 |
| β-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis RE Jenkins, FS Yaseen, MM Monshi, P Whitaker, X Meng, J Farrell, ... Chemical research in toxicology 26 (6), 963-975, 2013 | 72 | 2013 |
| An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules J Harper, KJ Adams, G Bossi, DE Wright, AR Stacey, N Bedke, ... PLoS One 13 (10), e0205491, 2018 | 66 | 2018 |
| Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy JP Sanderson, DJ Crowley, GE Wiedermann, LL Quinn, KL Crossland, ... OncoImmunology 9 (1), 1682381, 2020 | 65 | 2020 |
| Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate EC Border, JP Sanderson, T Weissensteiner, AB Gerry, NJ Pumphrey OncoImmunology 8 (2), e1532759, 2019 | 58 | 2019 |
| Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer RY Docta, T Ferronha, JP Sanderson, T Weissensteiner, GR Pope, ... Hepatology 69 (5), 2061-2075, 2019 | 54 | 2019 |
| Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A* 02+ patients: a phase 1 trial DS Hong, BA Van Tine, S Biswas, C McAlpine, ML Johnson, AJ Olszanski, ... Nature Medicine, 1-11, 2023 | 43 | 2023 |
| CD1d protein structure determines species‐selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cells JP Sanderson, PJ Brennan, S Mansour, G Matulis, O Patel, N Lissin, ... European journal of immunology 43 (3), 815-825, 2013 | 35 | 2013 |
| Structural and functional changes of the invariant NKT clonal repertoire in early rheumatoid arthritis S Mansour, AS Tocheva, JP Sanderson, LM Goulston, H Platten, L Serhal, ... The Journal of Immunology 195 (12), 5582-5591, 2015 | 33 | 2015 |
| Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer GR Blumenschein, S Devarakonda, M Johnson, V Moreno, J Gainor, ... Journal for immunotherapy of cancer 10 (1), 2022 | 21 | 2022 |
| Natural variations at position 93 of the invariant Vα24‐Jα18 α chain of human iNKT‐cell TCRs strongly impact on CD1d binding JP Sanderson, K Waldburger‐Hauri, D Garzón, G Matulis, S Mansour, ... European journal of immunology 42 (1), 248-255, 2012 | 17 | 2012 |
| Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury S El-Ghaiesh, JP Sanderson, J Farrell, SN Lavergne, WK Syn, ... Journal of Allergy and Clinical Immunology 128 (3), 680-683. e5, 2011 | 17 | 2011 |
| Drugs as haptens, antigens, and immunogens B Park, J Sanderson, D Naisbitt Drug Hypersensitivity, 55-65, 2007 | 15 | 2007 |
| T-cell populations in chronic pancreatitis J Jupp, S Mansour, CD Johnson, J Sanderson, D Fine, S Gadola Pancreatology: official journal of the International Association of …, 2015 | 11 | 2015 |
| Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β JD Silk, RJM Abbott, KJ Adams, AD Bennett, S Brett, TV Cornforth, ... The Journal of Immunology 208 (1), 169-180, 2022 | 10 | 2022 |
| Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors DS Hong, MO Butler, RK Pachynski, R Sullivan, P Kebriaei, ... Frontiers in oncology, 924, 2022 | 7 | 2022 |
Gurdyal BesraBardrick Professor of Microbial Physiology & Chemistryبريد إلكتروني تم التحقق منه على bham.ac.uk
